- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT00367237
Remicade Study in Psoriatic Arthritis Patients Of Methotrexate-Naïve Disease (RESPOND) (Study P04422)
A Randomized, Multicenter, International, Open-label Study of Infliximab Plus Methotrexate Versus Methotrexate (MTX) Alone for the Treatment of MTX naïve Subjects With Active Psoriatic Arthritis
Přehled studie
Postavení
Podmínky
Intervence / Léčba
Typ studie
Zápis (Aktuální)
Fáze
- Fáze 3
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
Inclusion Criteria:
- The subject must meet ALL of the criteria listed below for entry into the study:
- Subject must demonstrate their willingness to participate in the study and comply with its procedures by signing a written informed consent.
- Subject aged 18 years or more, of either sex and any race
Diagnosis of Psoriatic Arthritis with peripheral polyarticular involvement. Patients will have at least one of the following:
- Distal Interphalangeal Joints (DIP) involvement
- polyarticular arthritis, absence of rheumatoid nodules and presence of psoriasis
- arthritis mutilans
- asymmetric peripheral arthritis
- Negative rheumatoid factor
- The disease should have been diagnosed at least 3 months prior to screening.
Active disease at the time of screening and prior to receiving the baseline study medication(s) as defined by:
- 5 or more swollen joints and
- 5 or more tender joints
and one out of the following three categories:
- Erythrocyte Sedimentation Rate (ESR) >= 28 mm/h
- C-reactive protein (CRP) >= 15 mg/l
- Morning stiffness >= 45 min
- Subjects must confirm that they are practicing adequate contraception: Female subjects of childbearing potential (includes women who are less than 1 year postmenopausal and women who become sexually active during the study) must agree to use a medically accepted method of contraception or be surgically sterilized prior to screening, while receiving protocol-specified medication, and for 6 months after stopping the medication. Acceptable methods of contraception include condoms (male and female) with or without a spermicidal agent, diaphragm or cervical cap with spermicide, medically prescribed intrauterine device (IUD), oral or injectable hormonal contraceptive, and surgical sterilization (e.g., hysterectomy or tubal ligation).
- Female subjects of childbearing potential must have a negative pregnancy test at Screening.
- Subjects must be eligible for anti-tumor necrosis factor (TNF) treatment according to applicable local guidelines. For all patients chest X-ray and skin test results must be available at baseline.
- If using Nonsteroidal anti-inflammatory drugs (NSAIDs) or corticosteroids other than i.v., i.m. or i.a., the patient must be on a stable dose for four weeks prior screening (maximum dose up to 10mg/day of prednisone or its oral equivalent).
The screening laboratory tests must beet the following criteria:
- Hemoglobin >= 10 g/dl providing the low hemoglobin level is not due to other diseases than anemia of chronic inflammation.
- white blood cell (WBC) >= 3500 / μl
- Neutrophils >= 1500 / μl
- Platelets >= 100 000/ μl
- Aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase, and gamma-glutamyltransferase <= 1.5 x upper limit of normal
- Total bilirubin <= 1 x upper limit of normal
- Serum creatinine <= 1.5 mg/dl
- Patient must be able to adhere to the study visit schedule and other protocol requirements and must have given informed consent prior to any screening procedures.
Exclusion Criteria:
- The subject will be excluded from entry into the study if ANY of the criteria listed below are met:
- Subject is a female who is pregnant, intends to become pregnant during the study (or within 6 months after study completion), or nursing.
- Patients with other inflammatory diseases that might interfere with the evaluation of the psoriatic arthritis.
- Previous treatment with Infliximab.
- Subjects who have previously received MTX or have not discontinued their other DMARD therapy (i.e., sulfasalazine, hydroxychloroquine, leflunomide).
- Patients with fibromyalgia syndrome.
- Use of cyclosporine or tacrolimus within 4 weeks prior to screening. Use of IM, IV, or IA corticosteroids within 4 weeks prior to screening.
- Treatment with any investigational drug within 3 months prior to screening.
- Previous treatment with a monoclonal antibody or a fusion protein.
- A history of known allergy to murine proteins.
- History of infected joint prosthesis within the previous 5 years.
- Chronic infections.
- History of active tuberculosis requiring treatment within previous 3 years or history of opportunistic infections within 2 months, uncontrolled active infection or documented HIV infection. Also excluded are patients with evidence of latent tuberculosis and patients with old tuberculosis without documented adequate therapy, if they will not be treated according to local tuberculosis (TB) guidelines.
- Subject has any clinically significant deviation from normal in the physical examination, chest X-ray, or electrocardiogram (ECG) that, in the investigator's judgment, may interfere with the study evaluation or affect subject safety.
- Current signs or symptoms of other severe uncontrolled diseases, which in the investigators opinion would put the patient at an unacceptable risk.
- History of lymphoproliferative disease, any current malignancies or history of malignancy within 5 years other than successfully treated basal cell carcinoma or squamous cell carcinoma of the skin.
- Subject is part of the staff or a family member of the staff personnel directly involved with this study.
- History of drug abuse.
- Subjects who are participating in any other clinical study.
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Léčba
- Přidělení: Randomizované
- Intervenční model: Paralelní přiřazení
- Maskování: Žádné (otevřený štítek)
Zbraně a zásahy
Skupina účastníků / Arm |
Intervence / Léčba |
---|---|
Experimentální: Infliximab + methotrexate (IFX + MTX)
Remicade (infliximab [IFX]) 5 mg/kg infusions at Weeks 0, 2, 6, 14 and oral methotrexate (MTX) 15 mg/week
|
Infliximab 5 mg/kg infusion at Weeks 0, 2, 6, 14 and oral methotrexate 15 mg/week for 16 weeks.
Methotrexate dose can be increased to 20 mg/week at week 6.
Ostatní jména:
|
Aktivní komparátor: Methotrexate (MTX)
Oral methotrexate (MTX) 15 mg/week
|
Oral methotrexate 15 mg/week for 15 weeks.
Dose can be increased to 20 mg/week at Week 6.
Ostatní jména:
|
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
---|---|---|
Number of Subjects Achieving ACR20 (at Least 20% Improvement in American College of Rheumatology Criteria From Baseline) at Week 16
Časové okno: between baseline and week 16
|
>=20% improvement in swollen and tender joint count AND >=20% improvement in 3 of the following: visual analog scale (VAS) assessment of pain; subject VAS global assessment of disease activity; evaluator VAS global assessment of disease activity; Health Assessment Questionnaire (HAQ) disability index; C-Reactive Protein (CRP) level.
|
between baseline and week 16
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
---|---|---|
Proportion of Subjects Achieving ACR50, ACR70, and PASI75 if Applicable
Časové okno: between baseline and week 16
|
This is not a prespecified key secondary outcome; therefore, results will not be disclosed.
|
between baseline and week 16
|
Change in Disease Activity Score, Each of the ACR20 Domains, Dactylitis, Enthesitis, Fatigue and Duration of Morning Stiffness, Erythrocyte Sedimentation Rate, and Disability Index of the Health Assessment Questionnaire (HAQ)
Časové okno: between baseline and week 16
|
This is not a prespecified key secondary outcome; therefore, results will not be disclosed.
|
between baseline and week 16
|
Adverse Events
Časové okno: between baseline and week 16
|
This is not a prespecified key secondary outcome; therefore, results will not be disclosed.
|
between baseline and week 16
|
Spolupracovníci a vyšetřovatelé
Sponzor
Spolupracovníci
Publikace a užitečné odkazy
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia
Primární dokončení (Aktuální)
Dokončení studie (Aktuální)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Odhad)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Další relevantní podmínky MeSH
- Kožní choroby
- Onemocnění kloubů
- Nemoci pohybového aparátu
- Kožní onemocnění, papuloskvamózní
- Nemoci páteře
- Nemoci kostí
- Spondylartropatie
- Spondylartritida
- Spondylitida
- Psoriáza
- Artritida
- Artritida, psoriatika
- Fyziologické účinky léků
- Molekulární mechanismy farmakologického působení
- Inhibitory syntézy nukleových kyselin
- Inhibitory enzymů
- Antirevmatika
- Antimetabolity, Antineoplastika
- Antimetabolity
- Antineoplastická činidla
- Imunosupresivní látky
- Imunologické faktory
- Gastrointestinální látky
- Dermatologická činidla
- Činidla pro kontrolu reprodukce
- Abortivní látky, nesteroidní
- Abortivní látky
- Antagonisté kyseliny listové
- Methotrexát
- Infliximab
Další identifikační čísla studie
- P04422
- EUDRACT #: 2005-002189-12
Plán pro data jednotlivých účastníků (IPD)
Plánujete sdílet data jednotlivých účastníků (IPD)?
Popis plánu IPD
http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf
http://engagezone.msd.com/ds_documentation.php
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .
Klinické studie na Infliximab + methotrexate (IFX + MTX)
-
Children's Hospital of Fudan UniversityNáborCrohnova nemoc | Imunosuprese | Děti, Pouze | InfliximabČína
-
Groupe d'Etude Therapeutique des Affections Inflammatoires...DokončenoCrohnova nemocFrancie
-
Sixth Affiliated Hospital, Sun Yat-sen UniversityNáborStřední až těžká ulcerózní kolitidaČína
-
Chinese University of Hong KongDokončenoAnkylozující spondylitida
-
Children's Memorial Health Institute, PolandNeznámýCrohnova nemocPolsko
-
Centocor Ortho Biotech Services, L.L.C.Schering-PloughDokončenoCrohnova nemocSpojené státy, Francie, Spojené království, Německo, Španělsko, Belgie, Izrael, Řecko, Kanada, Holandsko, Rakousko, Norsko, Dánsko, Švédsko, Portugalsko
-
Rehab WeridaDokončenoZánětlivá onemocnění střevEgypt
-
Merck Sharp & Dohme LLCDokončeno
-
Helsinki University Central HospitalFoundation for Paediatric Research, Finland; Päivikki and Sakari Sohlberg Foundation... a další spolupracovníciDokončenoJuvenilní idiopatická artritidaFinsko